CONTENTS
Autumn/ Winter 2021
New Methods in Drug Development
When millions of vaccines are needed around the world, manufacturers set to work to find the quickest and most effective way to produce them. New plant-based innovations could alter the path for future vaccines forever.
Dissolution and the bioavailability of a drug candidate are two areas that are unassessed through prevalent high-throughput screening. A hot-melt extrusion platform is one novel approach that is helping to manufacture a high drug-loaded, amorphous, solid dispersion system.
Accelerating Processes
How pharma manufactures cells has evolved significantly; speed is of the essence, and by using techniques like continuous development, cell-line platforms can better support research timelines.
Machine learning, artificial intelligence, and robotics are supporting the development of better data gathering and interpretation, ensuring that the next generation of laboratories are ready to seamlessly glide into future innovations.
Cybersecurity is an issue that faces companies large and small across pharma manufacturing, but hidden behind the veil of added security are improvements to a company’s efficiency, speed, and reliability.
Microscopy
SPOT LIGHT
Wel-Screen’s experts in pharmaceutical technology and techniques deliver a wealth of analytics for detailing samples. Housing a range of services to support your science, including scanning electron microscopy and liquid chromatographymass spectroscopy, Wel-Sceen enhances your innovation.
It may seem easy to take a new drug from its particulate form to the end user, however in between lies a range of analyses that need to be conducted to ensure quality. Of those analyses is Raman microscopy, one of the most versatile techniques available.
Digital Health
The COVID-19 pandemic has provided an array of opportunities for digital health to permeate the life science industry, and this has offered the chance for digital mental health to come to the fore through more personalised wearables and apps.
How pharma companies function and operate between different roles can be the point of difference, and evolving the way this is organised across levels from healthcare professionals to the end customer can be vital.
The route from vaccine development to rollout has always tended to be years, rather than months. Moving out of the COVID-19 pandemic, the pharma industry can now look forward to speeding this process for the next vaccine that’s needed.
Data and automation in synergy offer a wealth of benefits to those utilising them. CROs collecting heaps of data will soon become reliant on burgeoning artificial intelligence technologies that can sort and understand healthcare data at speed.
Faced with a growing bank of data that shows no sign of halting, companies are choosing to place their faith in digital solutions. But, how can new software begin to compute the ever-increasing billions of cells that need to be categorised and validated?
Understanding data and knowing what to do with those gained insights has always been an area of improvement for life science companies. With the introduction of virtual and augmented reality, the sector can develop new ways of seeing and analysing data.
Genomics
Base and prime editing have followed one another into the genetic engineering world to provide an alternative to previous DNA technology. What does the future hold for these methods, and what can the industry expect from novel genome editors?
Neurological diseases, especially those involving paediatric patients, are of vital interest to biotechnology companies, with researchers delving into how genomics can provide a springboard for new and exciting treatment options.
Features
SPOT LIGHT
A new liquid flowmeter that introduces deeper analysis and more reliable parameters for HPLC separation results is now available and ready to support developers and manufacturers worldwide.
Over the last decade, 13 advanced therapy medicinal products were approved by the EMA, the attention now turns to how these vital medicines can be moved through the regulatory barriers in their way, and what can be done to help speed up the process.
Regulars
50 Events
Dive into the next quarter of events in the biotechnology and pharmaceutical industry stretching from California in the US to Essen, Germany, with a host of hybrid events to enjoy until the next IPT.
EXECUTIVE DIRECTOR
PMGroup Worldwide Ltd
Karl Equi
EDITORIAL MANAGER
Will Brown
EDITORIAL AND PRODUCTION ASSISTANT
George Grant
SALES
Helga Schweissguth
DESIGN
Peter May
FRONT COVER
Fishman64 – Shutterstock.com
DIGITAL EDITION
by Calaméo
www.calameo.com
CONTACT US
Tel: +44 (0)20 7724 3456
Fax: +44 (0)20 7403 7747
PRINTING
Hardings Print Solutions
www.hps-ltd.org.uk
SUBSCRIPTIONS AND DATA
Curwood CMS Ltd
Unit 9 Barns & Stables, Timworth Green,
IP31 1HS
c-cms.com
Tel: 01580 883841
Email: enquiries@c-cms.com
www.iptonline.com
Innovations in Pharmaceutical Technology (ISSN: 1471-7204, USPS No: 025082) is published four times a year – March, June, September, and December – by Samedan Ltd.
The opinions and views expressed by the authors in this book are not necessarily those of the Editor the Publisher and, while every care has been taken in the preparation of the book, the Editor and the Publisher are not responsible for such opinions and views or for
any inaccuracies in the articles.
The Publisher is not responsible for any images supplied by contributors. While every care is taken with artwork supplied, the Publisher cannot be held responsible for any loss or damage incurred.
The entire content of this publication is protected by copyright. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form, by any means – electronic,
mechanical, photocopying, or otherwise – without the prior permission of the Publisher.
© 2022 Samedan Ltd
Pharmaceutical Publishers